The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Open accessAbstract
Background: Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). Methods: This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level −1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). Results: From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4–26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3–4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Conclusions: Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months. Trial registration number NCT03277924 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sunitinib is a multi‐agent tyrosine kinase inhibitor (TKI) 35 , 36 that targets multiple proangiogenic and angiogenesis‐related receptors, such as platelet derived growth factor receptor α, KIT, stem cell factor, and vascular endothelial growth factor receptor 3. By inhibiting these receptors, sunitinib can reduce the production of growth factors that support tumor angiogenic supply and tumor grow”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sunitinib immunomodulation was shown active in soft tissue sarcoma (STS), 35 and it was associated with full dendritic cell maturation in a preclinical osteosarcoma model. 28”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [35]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The results of the phase 1b part, including both STS and BS cohorts, and the STS cohort of the phase 2 part of this study were already reported, 35 showing that sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced STS, with almost half of patients free from progression at 6 months.”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“The 6-month PFS rate for soft-tissue sarcoma patients was 48% (95% CI: 41–55%).”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [157]
The cited source says what the claim attributes to it.
In the citing paper
“The most common grade 3 or 4 side effects were transaminitis (17.3%) and neutropenia (11.5%) [157].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [157]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 2×
“Chondrosarcoma* 1 (6) 0 ECOG PS at baseline, n (%) 0 6 (37) 25 (48) 1 10 (63) 27 (52) Median previous lines (range) 1.”
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Tawbi, H. A., Burgess, M., Bolejack, V., Van Tine, B. A., Schuetze, S. M., Hu, J., D'Angelo, S., Attia, S., Riedel, R. F., Priebat, D. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30624-1 · Cited by 1,452
Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
Leone, R. D., Zhao, L., Englert, J. M., Sun, I.-M., Oh, M.-H., Sun, I.-H., Arwood, M. L., Bettencourt, I. A., Patel, C. H., Wen, J., et al. (2019) · Science · doi:10.1126/science.aav2588 · Cited by 1,169
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4734 · Cited by 841
Schöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E., Grignani, G., Camargo, V., Bauer, S., Rha, S. Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01283-0 · Cited by 778
Self-citationD'Angelo, S. P., Mahoney, M. R., Van Tine, B. A., Atkins, J., Milhem, M. M., Jahagirdar, B. N., Antonescu, C. R., Horvath, E., Tap, W. D., Schwartz, G. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30006-8 · Cited by 759
The parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Van Glabbeke, M., Verweij, J., Judson, I., & Nielsen, O. S. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00398-7 · Cited by 424
Zhu, Y., Yang, J., Xu, D., Gao, X.-M., Zhang, Z., Hsu, J. L., Li, C.-W., Lim, S.-O., Sheng, Y.-Y., Zhang, Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318419 · Cited by 419
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 360
George, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9890 · Cited by 321
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S., Reed, D., Chawla, S. P., Riedel, R. F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30381-9 · Cited by 302
Self-citationD’Angelo, S. P., Shoushtari, A. N., Agaram, N. P., Kuk, D., Qin, L.-X., Carvajal, R. D., Dickson, M. A., Gounder, M., Keohan, M. L., Schwartz, G. K., et al. (2015) · Human Pathology · doi:10.1016/j.humpath.2014.11.001 · Cited by 301
Pollack, S. M., He, Q., Yearley, J. H., Emerson, R., Vignali, M., Zhang, Y., Redman, M. W., Baker, K. K., Cooper, S., Donahue, B., et al. (2017) · Cancer · doi:10.1002/cncr.30726 · Cited by 274
Tumor Microenvironment, Metabolism, and Immunotherapy
DeBerardinis, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmcibr1914890 · Cited by 266
Patterns of Human Tumor-Infiltrating Lymphocytes in 120 Human Cancers
Balch, C. M. (1990) · Archives of Surgery · doi:10.1001/archsurg.1990.01410140078012 · Cited by 241
Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., et al. (2017) · Cancer · doi:10.1002/cncr.30738 · Cited by 226
Ryan, C. W., Merimsky, O., Agulnik, M., Blay, J.-Y., Schuetze, S. M., Van Tine, B. A., Jones, R. L., Elias, A. D., Choy, E., Alcindor, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6684 · Cited by 210
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Dancsok, A. R., Setsu, N., Gao, D., Blay, J., Thomas, D. M., Maki, R. G., Nielsen, T. O., & Demicco, E. G. (2019) · Modern Pathology · doi:10.1038/s41379-019-0312-y · Cited by 107
Inaguma, S., Wang, Z., Lasota, J. P., Sarlomo‐Rikala, M., McCue, P. A., Ikeda, H., & Miettinen, M. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000653 · Cited by 98
Judson, I. R., Morden, J. P., Kilburn, L., Leahy, M. G., Benson, C., Bhadri, V. A., Campbell‐Hewson, Q., Cubedo, R., Dangoor, A., Fox, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30215-3 · Cited by 98
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas
Bertucci, F., Finetti, P., Perrot, D., Leroux, A., Collin, F., Cesne, A. L., Coindre, J., Blay, J., Birnbaum, D., & Mamessier, É. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1278100 · Cited by 93
PD-1 and PD-L1 expression in bone and soft tissue sarcomas
Torabi, A., Amaya, C. N., Wians, F. H., & Bryan, B. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.05.003 · Cited by 80
Martín‐Broto, J., Pousa, A. L., Peñas, R. D. L., del Muro, X. G., Gutierrez, A. M., Martínez‐Trufero, J., Cruz, J., Alvarez, R. M., Cubedo, R., Redondo, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.3329 · Cited by 74
Self-citationPrognostic impact of the tumor immune microenvironment in synovial sarcoma
Oike, N., Kawashima, H., Ogose, A., Hotta, T., Hatano, K., Ariizumi, T., Sasaki, T., Yamagishi, T., Umezu, H., & Endo, N. (2018) · Cancer Science · doi:10.1111/cas.13769 · Cited by 69
Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Lewin, J. H., Davidson, S., Anderson, N. D., Lau, B. Y., Kelly, J., Tabori, U. Y., Salah, S. H., Butler, M. O., Aung, K. L., Shlien, A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0037 · Cited by 56
Penel, N., Demetri, G. D., Blay, J., Cousin, S., Maki, R. G., Chawla, S. P., Judson, I. R., von Mehren, M., Schöffski, P., Verweij, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds470 · Cited by 53
Status of programmed death-ligand 1 expression in sarcomas
Park, H. K., Kim, M., Sung, M., Lee, S. E., Kim, Y. J., & Choi, Y. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1658-5 · Cited by 40
Myelosuppression by sunitinib is flt-3 genotype dependent
van Erp, N. P., Mathijssen, R. H. J., van der Veldt, A. A., Haanen, J. B. A. G., Reyners, A. K. L., Eechoute, K., Boven, E., Wessels, J. A. M., Guchelaar, H., & Gelderblom, H. A. J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605813 · Cited by 19
Cited by
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 270
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“[157].”
New clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B.-D., Jiao, X.-D., Liu, K., Wang, Z., & Zang, Y.-S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 197
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Martin-Broto, J., Mondaza-Hernandez, J. L., Moura, D. S., & Hindi, N. (2021) · Cancers · doi:10.3390/cancers13122913 · Cited by 184
Self-citationAtezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen, A. P., Sharon, E., O’Sullivan-Coyne, G., Moore, N., Foster, J. C., Hu, J. S., Van Tine, B. A., Conley, A. P., Read, W. L., Riedel, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303383 · Cited by 166
Metadata
- Authors
- Martin-Broto, J., Hindi, N., Grignani, G., Martinez-Trufero, J., Redondo, A., Valverde, C., Stacchiotti, S., Lopez-Pousa, A., D'Ambrosio, L., Gutierrez, A., Perez-Vega, H., Encinas-Tobajas, V., de Alava, E., Collini, P., Peña-Chilet, M., Dopazo, J., Carrasco-Garcia, I., Lopez-Alvarez, M., Moura, D. S., & Lopez-Martin, J. A.
- Affiliations
- Medical Oncology Department, University Hospital Virgen del Rocio, Sevilla, Spain
- Instituto de Biomedicina de Sevilla (ES)
- Candiolo Cancer Institute (IT)
- Medical Oncology Department, Miguel Servet University Hospital, Zaragoza, Spain
- Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain
- Vall d'Hebron Hospital Universitari (ES)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Medical Oncology Department, Sant Pau Hospital, Barcelona, Spain
- Division of Medical Oncology, Candiolo Cancer Institute, FPO - IRCCS - Str. Prov.le 142, km. 3,95 - Candiolo (TO) 10060, Candiolo, Italy
- Hospital Universitario Son Espases (ES)
- Radiology Department, University Hospital Virgen del Rocio, Sevilla, Spain
- Hospital Universitario Virgen del Rocío (ES)
- Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital /CSIC/University of Sevilla/CIBERONC, Sevilla, Spain
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Institute of Biomedicine of Sevilla (IBIS, HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain
- Research Institute Hospital 12 de Octubre (ES)
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2020-11
- Volume
- 8
- Issue
- 2
- Pages
- e001561
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC7674086
- OpenAlex
- W3100757401
- Cited by
- 183
- References
- 35
- Citations by year
- 2026: 18 · 2025: 37 · 2024: 37 · 2023: 36 · 2022: 34 · 2021: 20 · 2020: 1
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc)
- Hispana (submittedVersion, cc-by-nc)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by-nc)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by-nc)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nc)
- Funders
- Beca Buesa (NA)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Vascular Tumors and Angiosarcomas
- Keywords
- nivolumab, sunitinib, soft tissue sarcoma, PD-1/PD-L1 blockade, angiogenesis inhibition, combination immunotherapy, tumor microenvironment, cold tumor conversion, progression-free survival, dose escalation, elevated liver enzymes, neutropenia
- MeSH terms
- Antineoplastic Agents, Immunological, Sunitinib, Nivolumab, Adult, Aged, Female, Humans, Male, Middle Aged, Sarcoma, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.